G6PD Knockout A-549 Cell Line

The choice depends on whether you are studying G6PD (glucose-6-phosphate dehydrogenase)'s role as the rate-limiting enzyme of the pentose phosphate pathway (PPP) or modeling G6PD deficiency (the world's most common human enzyme deficiency, affecting ~400 million people). The Knockout line is the standard tool for asking whether G6PD is required for these processes — G6PD catalyzes glucose-6-phosphate to 6-phosphogluconolactone (the first step of PPP), generating NADPH for cellular antioxidant defense (GSH regeneration via GSR) and reductive biosynthesis (lipid, nucleotide synthesis). Overexpression is useful for studying G6PD in heterologous expression contexts. For redox biology and cancer research, the EDITGENE G6PD Knockout in A-549 is highly relevant — A-549 is an NSCLC cell line, and G6PD has emerged as a target in cancer metabolism for limiting NADPH-dependent antioxidant defense. Rescue with wild-type or G6PD-deficiency variants (A-, A+, Mediterranean) enables disease genotype-function studies. The knockout is a critical specificity control for G6PD inhibitors (DHEA, polydatin, 6-AN) in cancer drug development, and for studying favism-related drug sensitivities (primaquine, rasburicase, dapsone, sulfonamides cause oxidative hemolysis in G6PD-deficient individuals).

Primary applications: • PPP flux: ¹³C-glucose tracing into 6-phosphogluconate, ribose-5-phosphate, and NADPH levels in G6PD-null cells. • NADPH/NADP+ redox balance: cellular NADPH levels and GSH/GSSG ratio analysis given G6PD's role as the principal NADPH source. • G6PD deficiency modeling: rescue with G6PD A-, A+, Mediterranean, Canton, and other deficiency variants for genotype-function studies. • Favism drug specificity: critical genetic control for primaquine, rasburicase, dapsone, sulfonamide oxidative stress mechanism studies — these drugs cause hemolysis in G6PD-deficient individuals. • G6PD inhibitor specificity: DHEA, polydatin, 6-AN inhibitor specificity testing in cancer drug development. EDITGENE recommends this lung cancer model for researchers investigating PPP biology, NADPH-dependent antioxidant defense, G6PD deficiency, and G6PD-targeted cancer therapeutics.

Yes. G6PD rescue experiments are well-established for PPP and redox biology research: • Construct design: use a codon-modified G6PD sequence with a small C-terminal tag (FLAG, HA). G6PD has NADP+ binding sites, substrate binding pocket, and dimer/tetramer interface — preserve all elements. • Catalytically-dead rescue: substrate-binding pocket mutations abolish dehydrogenase activity and serve as the standard specificity control. • Deficiency variant rescue: G6PD A- (Class III deficiency), Mediterranean (Class II), Canton, Kaiping, and other deficiency variants for disease genotype-function studies. • Functional readout: rescue should restore NADPH generation and PPP flux measured by ¹³C-glucose tracing. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.